| The convalescent sera option for containing COVID-19 #MMPMID32167489Casadevall A; Pirofski LAJ Clin Invest 2020[Apr]; 130 (4): 1545-1548 PMID32167489show ga
ä|Antibodies, Viral/blood/*therapeutic use[MESH]|Betacoronavirus/*immunology[MESH]|Blood Donors[MESH]|COVID-19[MESH]|COVID-19 Serotherapy[MESH]|Coronavirus Infections/blood/history/*immunology/*therapy[MESH]|History, 20th Century[MESH]|History, 21st Century[MESH]|Humans[MESH]|Immunization, Passive/adverse effects/history/methods/standards[MESH]|Pandemics[MESH]|Pneumonia, Viral/blood/*immunology/*therapy[MESH]|Risk Assessment[MESH]
DeepDyve Pubget Overpricing |
|